Varivax (varicella virus vaccine live) / Merck (MSD) - LARVOL DELTA

SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (clinicaltrials.gov) - P3 | N=780 | Recruiting | Sponsor: SK Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Varicella Zoster

Varivax (Aesculus hippocastanum L.): A dietary supplement with antioxidant and antidepressant potential in adult zebrafish. (PubMed, IBRO Neurosci Rep) - "Varivax (Natulab®) is a dietary supplement composed of dry extract of horse chestnut (Aesculus hippocastanum L.), standardized to 20% anhydrous escin and indicated for chronic venous insufficiency, pain, and leg swelling...The results of in vivo and in silico analyses demonstrated that VRX exhibited an antidepressant effect at the highest dose tested, with a response comparable to fluoxetine. The present study highlights the medicinal potential of this supplement in the prospecting of phytopharmaceuticals for depression."

Journal • Cardiovascular • CNS Disorders • Depression • Pain • Psychiatry

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Safety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis. (PubMed, Vaccines (Basel)) - "LAVs were not associated with an increased risk of adverse outcomes within one day to six months among IBD patients receiving immunomodulatory therapy. These real-world findings suggest comparable short-term outcomes between the cohorts of patients with IBD receiving biologic or targeted synthetic therapy who met the predefined eligibility criteria including age ≥ 18 years, and vaccination occurring between two weeks and six months after biologic initiation regarding LAV use in patients with IBD receiving biologic agents."

Journal • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Measles • Mumps • Oncology • Rubella • Ulcerative Colitis • Varicella Zoster • IL23A

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=750 | Recruiting | Sponsor: GlaxoSmithKline | Trial primary completion date: Jul 2026 ➔ Nov 2026

Trial primary completion date • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: GlaxoSmithKline | N=354 ➔ 900

Enrollment change • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2360 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting | Trial completion date: May 2027 ➔ Oct 2027 | Trial primary completion date: May 2027 ➔ Oct 2027

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=1840 | Recruiting | Sponsor: GlaxoSmithKline | N=199 ➔ 1840

Enrollment change • Infectious Disease • Varicella Zoster

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=750 | Recruiting | Sponsor: GlaxoSmithKline | N=385 ➔ 750

Enrollment change • Infectious Disease • Varicella Zoster

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years (clinicaltrials.gov) - P3 | N=474 | Recruiting | Sponsor: GC Biopharma Corp | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Infectious Disease • Varicella Zoster

Comparative analysis of the impact of chickenpox and herpes zoster vaccination in Belgium under two different exogenous boosting mechanisms. (PubMed, PLoS One) - "Both models predicted that universal CP vaccination would result in significant reductions in the burden of CP disease, however, the HZ disease burden impact varied significantly depending on the assumed boosting mechanism. Hence, the choice of modeled exogenous boosting mechanism leads to different optimal vaccination strategies. Ascertaining the relative accuracy of these structural model choices will require continued research on the mechanism of VZV boosting."

Clinical • Journal • Herpes Zoster • Infectious Disease • Varicella Zoster

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1092 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1714 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (clinicaltrials.gov) - P3 | N=780 | Not yet recruiting | Sponsor: SK Bioscience Co., Ltd.

New P3 trial • Infectious Disease • Varicella Zoster

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

CORAL: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (clinicaltrials.gov) - P3 | N=2226 | Terminated | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Terminated; Sponsor decision

Trial termination • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Safety of Live Vaccines in Patients With Inflammatory Bowel Disease on Biologic Therapy: A Propensity Score Matched Analysis (ACG 2025) - "Biologic therapies included tumor necrosis factor inhibitors (infliximab, adalimumab), integrin antagonists (vedolizumab), interleukin-12/23 inhibitors (ustekinumab), interleukin-23 inhibitors (risankizumab, guselkumab), and Janus kinase inhibitors (tofacitinib, upadacitinib)... A total of 758 patients were included in each matched cohort. No significant increase in adverse events was observed in the vaccinated group compared to the unvaccinated group. Inpatient visits occurred in 8.7% vs 9.1% (risk ratio [RR] 0.95; 95% confidence interval [CI]: 0.55–1.65; p=0.866), and ED visits in 6.4% vs 8.3% (RR 0.78; 95% CI: 0.48–1.25; p=0.298)."

Clinical • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Measles • Mumps • Pneumonia • Respiratory Diseases • Rubella • Septic Shock • Ulcerative Colitis • Varicella Zoster • IL12A

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Healthy Children Aged 12 to 15 Months: A Phase III, Randomized, Double-Blind, Active-Controlled Clinical Trial. (PubMed, Vaccines (Basel)) - " Sinovac's VarV demonstrated non-inferior immunogenicity to WHO-prequalified comparator vaccine (VARIVAX®) and favorable safety profile. These findings indicated that VarV (Sinovac, Beijing, China) met WHO standards for varicella vaccine evaluation, supporting its global use consideration."

Clinical • Journal • P3 data • Herpes Zoster • Varicella Zoster

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years (clinicaltrials.gov) - P3 | N=474 | Not yet recruiting | Sponsor: GC Biopharma Corp

Head-to-Head • New P3 trial • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (clinicaltrials.gov) - P2 | N=76 | Completed | Sponsor: Memorial Sloan Kettering Cancer Center | Active, not recruiting ➔ Completed

Trial completion • Oncology